ANL (Adlai Nortye) EBITDA Margin %: -328.42% (As of Dec. 2025)


What is Adlai Nortye EBITDA Margin %?

Adlai Nortye ANL -1.57% EBITDA Margin % is -328.42% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 944 Biotechnology companies, Adlai Nortye ranks worse than 75.42% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Adlai Nortye's EBITDA for the six months ended in Dec. 2025 was $-16.42 Mil. Adlai Nortye's Revenue for the six months ended in Dec. 2025 was $5.00 Mil. Therefore, Adlai Nortye's EBITDA margin for the quarter that ended in Dec. 2025 was -328.42%.

Adlai Nortye  (NAS:ANL) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Adlai Nortye EBITDA Margin % Related Terms

Adlai Nortye EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye EBITDA Margin % Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
-117.03 0.00 0.00 0.00 -652.54

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 -328.42

ANL vs PHAT, AURA, RLMD: EBITDA Margin % Comparison

For the Biotechnology subindustry, Adlai Nortye's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's EBITDA Margin % falls into.


Adlai Nortye EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Adlai Nortye's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-32.627/5
=-652.54 %

Adlai Nortye's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-16.421/5
=-328.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -328.42% mean?
Adlai Nortye (ANL) has a EBITDA Margin % of -328.42% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #712 out of 944 companies in the Biotechnology industry, placing it in the top 75.4%.
Is Adlai Nortye's EBITDA Margin % too high?
Adlai Nortye's current EBITDA Margin % is -328.42%. Based on the distribution chart, Adlai Nortye ranks #712 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's EBITDA Margin % compare to PHAT and AURA?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #712 out of 944 companies for EBITDA Margin %. This places Adlai Nortye in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current EBITDA Margin % is -328.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current EBITDA Margin % of -328.42%. The current EBITDA Margin % is -328.42%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Adlai Nortye (ANL), the current EBITDA Margin % is -328.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.